 SAN JOSE, Calif., Nov. 25, 2020 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we NASDAQ: ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approximately 100 in 2020 over 2019, with a revenue range of US3 million RMB20 million to US3.3 million RMB22 million. For 2019, the Company had a revenue of US1.6 million RMB10.9 million using a current US to RMB exchange ratio of 6.6. We expect the strong momentum of YoY revenue growth due to market demand and customers accepting AnPac Bios novel cancer screening technology with multiple advantages named cancer differentiation analysis CDA technology to continue into 2021. The Company plans to release its full year 2020 audited financial report in early March 2021. 